指南与共识肝病消化道出血

AGA临床实践更新:血管活性药物与静脉白蛋白在肝硬化中的应用专家综述

AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review.
指南 / 共识 · Gastroenterology · 2023-11-18

美国胃肠病学会(AGA)发布的专家综述,针对肝硬化患者中血管活性药物和静脉白蛋白的使用提出12条最佳实践建议,涵盖食管胃静脉曲张出血、腹水与自发性细菌性腹膜炎、肝肾综合征三个场景。该综述基于文献回顾和专家意见,未进行系统评价,因此建议未附正式的证据质量或推荐强度评级。

要点

  • 怀疑或确诊静脉曲张出血时应尽早开始血管活性药物,最好在内镜诊治前。
  • 大量放腹水(>5 L)时应给予静脉白蛋白;自发性细菌性腹膜炎患者可考虑静脉白蛋白。
  • 肝肾综合征-急性肾损伤(HRS-AKI)治疗选用血管活性药物联合白蛋白,特利加压素为首选。

核心结论

  • 该专家综述就肝硬化患者中血管活性药物和静脉白蛋白的使用提出12条最佳实践建议,涉及静脉曲张出血、腹水和自发性细菌性腹膜炎、肝肾综合征三个场景。

研究设计与样本

  • 由美国胃肠病学会(AGA)研究所临床实践更新委员会和AGA理事会委托并批准的专家综述,经《Gastroenterology》标准内部同行评议。
  • 建议来自已发表文献回顾和专家意见,未进行系统评价,因此建议未附正式的证据质量或推荐强度评级。
  • 部分建议因文献缺乏新证据而与已发表指南相同。

主要发现

  • 肝硬化分为代偿期、失代偿期和进一步失代偿期,中位生存期分别超过15年、2年和9个月。
  • 血管收缩剂通过内脏血管收缩降低门静脉压力,用于静脉曲张出血管理;静脉白蛋白增加有效动脉血容量,用于大量放腹水后和自发性细菌性腹膜炎患者预防急性肾损伤(AKI)和死亡。
  • 血管收缩剂联合白蛋白用于逆转肝肾综合征(HRS-AKI),这是肝硬化最致命的并发症。

关键数值与推荐

  • 最佳实践建议1:怀疑或确诊静脉曲张出血时应尽早开始血管活性药物,最好在诊断和/或治疗性内镜前。
  • 最佳实践建议2:初始内镜止血后,血管活性药物应继续使用2-5天以预防早期再出血。
  • 最佳实践建议3:基于安全性特征,奥曲肽是静脉曲张出血管理中首选的血管活性药物。
  • 最佳实践建议4:大量放腹水(>5 L)时应给予静脉白蛋白。
  • 最佳实践建议5:自发性细菌性腹膜炎患者可考虑静脉白蛋白。

临床怎么用

  • 该综述为肝硬化患者中血管活性药物和静脉白蛋白的使用提供最佳实践建议,供临床医生参考。

局限性

  • 未进行系统评价,因此建议未附正式的证据质量或推荐强度评级。
  • 部分建议因文献缺乏新证据而与已发表指南相同。
  • 建议基于文献回顾和专家意见。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DESCRIPTION: Cirrhosis is a major cause of morbidity and mortality in the United States and worldwide. It consists of compensated, decompensated, and further decompensated stages; median survival is more than 15 years, 2 years, and 9 months for each stage, respectively. With each stage, there is progressive worsening of portal hypertension and the vasodilatory-hyperdynamic circulatory state, resulting in a progressive decrease in effective arterial blood volume and renal perfusion. Vasoconstrictors reduce portal pressure via splanchnic vasoconstriction and are used in the management of variceal hemorrhage. Intravenous (IV) albumin increases effective arterial blood volume and is used in the prevention of acute kidney injury (AKI) and death after large-volume paracentesis and in patients with spontaneous bacterial peritonitis (SBP). The combination of vasoconstrictors and albumin is used in the reversal of hepatorenal syndrome (HRS-AKI), the most lethal complication of cirrhosis. Because a potent vasoconstrictor, terlipressin, was recently approved by the US Food and Drug Administration, and because recent trials have explored use of IV albumin in other settings, it was considered that a best practice update would be relevant regarding the use of vasoactive drugs and IV albumin in the following 3 specific scenarios: variceal hemorrhage, ascites and SBP, and HRS. METHODS: This expert review was commissioned and approved by the American Gastroenterological Association (AGA) Institute Clinical Practice Updates Committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership. It underwent internal peer review through standard procedures of Gastroenterology. These Best Practice Advice statements were drawn from a review of the published literature and from expert opinion. Some of the statements are unchanged from published guidelines because of lack of new evidence in the literature. Because systematic reviews were not performed, these Best Practice Advice statements do not carry formal ratings regarding the quality and evidence or strength of the presented considerations. Best Practice Advice Statements BEST PRACTICE ADVICE 1: Vasoactive drugs should be initiated as soon as the diagnosis of variceal hemorrhage is suspected or confirmed, preferably before diagnostic and/or therapeutic endoscopy. BEST PRACTICE ADVICE 2: After initial endoscopic hemostasis, vasoactive drugs should be continued for 2-5 days to prevent early rebleeding. BEST PRACTICE ADVICE 3: Octreotide is the vasoactive drug of choice in the management of variceal hemorrhage based on its safety profile. BEST PRACTICE ADVICE 4: IV albumin should be administered at the time of large-volume (>5 L) paracentesis. BEST PRACTICE ADVICE 5: IV albumin may be considered in patients with SBP. BEST PRACTICE ADVICE 6: Albumin should not be used in patients (hospitalized or not) with cirrhosis and uncomplicated ascites. BEST PRACTICE ADVICE 7: Vasoconstrictors should not be used in the management of uncomplicated ascites, after large-volume paracentesis or in patients with SBP. BEST PRACTICE ADVICE 8: IV albumin is the volume expander of choice in hospitalized patients with cirrhosis and ascites presenting with AKI. BEST PRACTICE ADVICE 9: Vasoactive drugs (eg, terlipressin, norepinephrine, and combination of octreotide and midodrine) should be used in the treatment of HRS-AKI, but not in other forms of AKI in cirrhosis. BEST PRACTICE ADVICE 10: Terlipressin is the vasoactive drug of choice in the treatment of HRS-AKI and use of concurrent albumin can be considered when accounting for patient's volume status. BEST PRACTICE ADVICE 11: Terlipressin treatment does not require intensive care unit monitoring and can be administered intravenously through a peripheral line. BEST PRACTICE ADVICE 12: Terlipressin use is contraindicated in patients with hypoxemia and in patients with ongoing coronary, peripheral, or mesenteric ischemia, and should be used with caution in patients with acute-on-chronic liver failure grade 3. The benefits may not outweigh the risks in patients with serum creatinine >5 mg/dL and in patients listed for transplantation with a Model for End-stage Liver Disease ≥35.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Garcia-Tsao G, Abraldes JG, Rich NE, et al. AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review. Gastroenterology. 2023. PMID: 37978969. doi:10.1053/j.gastro.2023.10.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。